Lornoxicam + Paracetamol in pharma franchise in Meghalaya

Lornoxicam + Paracetamol in PCD pharma franchise in Gandhinagar

Lornoxicam + Paracetamol in top pharma company in Alwar

Lornoxicam + Paracetamol in pcd pharma supplier in Kottayam

Lornoxicam + Paracetamol in phama franchise company in India
Lornoxicam + Paracetamol in phama distributor in Kollam

Home/Products /lornoxicam-8mg-paracetamol-325mg-tablet

Loxifrit P Tablet

Composition : Lornoxicam (8mg) + Paracetamol (325mg)

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹130/-

Loxifrit P Tablet is a combination of Lornoxicam (8mg) and Paracetamol (325mg), designed to provide effective pain relief and reduce inflammation. Lornoxicam belongs to the non-steroidal anti-inflammatory drugs (NSAIDs) category and works by inhibiting prostaglandin synthesis, which is responsible for pain and inflammation. Paracetamol complements this action by providing analgesic and antipyretic effects, making the combination highly effective in managing pain and fever associated with various conditions.

This formulation is widely prescribed for the symptomatic relief of mild to moderate pain, including musculoskeletal disorders, postoperative pain, dental pain, and osteoarthritis. It also helps reduce inflammation, making it suitable for conditions where swelling and discomfort coexist. The combination of Lornoxicam and Paracetamol ensures comprehensive relief by targeting both the inflammatory and central pain pathways.

The dual-action mechanism of Loxifrit P Tablet offers fast and long-lasting relief, improving patient compliance and quality of life. It is recommended to take this medication with or after meals to minimize gastrointestinal side effects commonly associated with NSAIDs.

Read More

About the Product

Loxifrit P Tablet is a combination of Lornoxicam (8mg) and Paracetamol (325mg), designed to provide effective pain relief and reduce inflammation. Lornoxicam belongs to the non-steroidal anti-inflammatory drugs (NSAIDs) category and works by inhibiting prostaglandin synthesis, which is responsible for pain and inflammation. Paracetamol complements this action by providing analgesic and antipyretic effects, making the combination highly effective in managing pain and fever associated with various conditions.

This formulation is widely prescribed for the symptomatic relief of mild to moderate pain, including musculoskeletal disorders, postoperative pain, dental pain, and osteoarthritis. It also helps reduce inflammation, making it suitable for conditions where swelling and discomfort coexist. The combination of Lornoxicam and Paracetamol ensures comprehensive relief by targeting both the inflammatory and central pain pathways.

The dual-action mechanism of Loxifrit P Tablet offers fast and long-lasting relief, improving patient compliance and quality of life. It is recommended to take this medication with or after meals to minimize gastrointestinal side effects commonly associated with NSAIDs.

Common side effects may include nausea, vomiting, abdominal discomfort, heartburn, and dizziness. In rare cases, patients may experience gastrointestinal bleeding, skin rash, or allergic reactions. Prolonged use or overdose may affect liver or kidney function.

Relief from mild to moderate pain due to musculoskeletal conditions, dental pain, or postoperative discomfort. Management of inflammatory conditions, including arthritis and osteoarthritis. Reduction of fever and associated symptoms.

Do not use this medication if you are allergic to Lornoxicam, Paracetamol, or NSAIDs. Avoid alcohol consumption while using this medication to prevent liver damage. Consult a doctor if you are pregnant, breastfeeding, or have pre-existing liver, kidney, or gastrointestinal conditions.

Store Loxifrit P Tablet in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children and do not use the medication past its expiration date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation